Hansoh Pharma's Roche Deal Could Help Unlock Commercial Potential -- Market Talk

Dow Jones

Oct 20

0804 GMT - Hansoh Pharmaceutical Group's new out-licensing deal with Roche could help to unlock the commercial potential of its anti-body drug conjugate, says Nomura's Jialin Zhang in a note. The deal, in which Hansoh Pharmaceutical will receive US$80 million up front, is likely to contribute up to 10% of Nomura's projected 2025 earnings estimates for the Chinese healthcare company, says Zhang. The agreement with Roche also endorses Hansoh's research and development capability, Nomura says, noting that this could contribute to making Hansoh's drug commercially-viable. Nomura raises its estimated 2026 revenue and earnings for Hansoh by 3.2% and 3.8%, respectively. The bank lifts its target price to HK$35.50 from HK$35.47 while maintaining its neutral rating on Hansoh. Shares fall 0.2% to HK$36.34. (megan.cheah@wsj.com)

(END) Dow Jones Newswires

October 20, 2025 04:04 ET (08:04 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2576836064"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2576836064\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2576836064?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-20 16:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2576836064","market":"hk","top_or_hot":-1,"title":"Hansoh Pharma's Roche Deal Could Help Unlock Commercial Potential -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0804 GMT - Hansoh Pharmaceutical Group's new out-licensing deal with Roche could help to unlock the commercial potential of its anti-body drug conjugate, says Nomura's Jialin Zhang in a note. The deal, in which Hansoh Pharmaceutical will receive US$80 million up front, is likely to contribute up to 10% of Nomura's projected 2025 earnings estimates for the Chinese healthcare company, says Zhang. The agreement with Roche also endorses Hansoh's research and development capability, Nomura says, noting that this could contribute to making Hansoh's drug commercially-viable. Nomura raises its estimated 2026 revenue and earnings for Hansoh by 3.2% and 3.8%, respectively. The bank lifts its target price to HK$35.50 from HK$35.47 while maintaining its neutral rating on Hansoh. Shares fall 0.2% to HK$36.34. (megan.cheah@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 20, 2025 04:04 ET (08:04 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hansoh Pharma's Roche Deal Could Help Unlock Commercial Potential -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHansoh Pharma's Roche Deal Could Help Unlock Commercial Potential -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-20 16:04</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0804 GMT - Hansoh Pharmaceutical Group's new out-licensing deal with Roche could help to unlock the commercial potential of its anti-body drug conjugate, says Nomura's Jialin Zhang in a note. The deal, in which Hansoh Pharmaceutical will receive US$80 million up front, is likely to contribute up to 10% of Nomura's projected 2025 earnings estimates for the Chinese healthcare company, says Zhang. The agreement with Roche also endorses Hansoh's research and development capability, Nomura says, noting that this could contribute to making Hansoh's drug commercially-viable. Nomura raises its estimated 2026 revenue and earnings for Hansoh by 3.2% and 3.8%, respectively. The bank lifts its target price to HK$35.50 from HK$35.47 while maintaining its neutral rating on Hansoh. Shares fall 0.2% to HK$36.34. (megan.cheah@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 20, 2025 04:04 ET (08:04 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1589","symbol_name":"北水核心资产","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2576836064","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2576836064","pubTimestamp":1760947440,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0804 GMT - Hansoh Pharmaceutical Group's new out-licensing deal with Roche could help to unlock the commercial potential of its anti-body drug conjugate, says Nomura's Jialin Zhang in a note. The deal, in which Hansoh Pharmaceutical will receive US$80 million up front, is likely to contribute up to 10% of Nomura's projected 2025 earnings estimates for the Chinese healthcare company, says Zhang. The agreement with Roche also endorses Hansoh's research and development capability, Nomura says, noting that this could contribute to making Hansoh's drug commercially-viable. Nomura raises its estimated 2026 revenue and earnings for Hansoh by 3.2% and 3.8%, respectively. The bank lifts its target price to HK$35.50 from HK$35.47 while maintaining its neutral rating on Hansoh. Shares fall 0.2% to HK$36.34. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1589":"北水核心资产","BK1191":"制药","BK1583":"高瓴概念","03692":"翰森制药"},"translate_title":"翰森制药与罗氏的交易可能有助于释放商业潜力——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":0.9},"content_text":"0804 GMT - Hansoh Pharmaceutical Group's new out-licensing deal with Roche could help to unlock the commercial potential of its anti-body drug conjugate, says Nomura's Jialin Zhang in a note. The deal, in which Hansoh Pharmaceutical will receive US$80 million up front, is likely to contribute up to 10% of Nomura's projected 2025 earnings estimates for the Chinese healthcare company, says Zhang. The agreement with Roche also endorses Hansoh's research and development capability, Nomura says, noting that this could contribute to making Hansoh's drug commercially-viable. Nomura raises its estimated 2026 revenue and earnings for Hansoh by 3.2% and 3.8%, respectively. The bank lifts its target price to HK$35.50 from HK$35.47 while maintaining its neutral rating on Hansoh. Shares fall 0.2% to HK$36.34. (megan.cheah@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 20, 2025 04:04 ET (08:04 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}